OBJECTIVES: The aim of this study was to evaluate the budget impact of modern anti-Parkinson drugs in monotherapy early Parkinson's disease in the Russian Federation. METHODS: For analysis of market data regarding Parkinson's disease (PD) treatment products we used IMS Health Russia database (2014). The target population was newly diagnosed PD patients over 60 years in the early clinical stages. The time horizon for this analysis was taken for 1-year period. Comparison drugs: pramipexole ER, piribedil CR, ropinirole ER and rasagiline. In the analysis we have only taken the cost of anti-Parkinson therapy and a possible change of therapy due to ineffectiveness into account assumed that the cost for correction of adverse reactions is a patient cost. The cost of switching therapy due to ineffectiveness was calculated based on the assumption that the prescription probability for each comparator is 33.3%. Effectiveness of the anti-Parkinson drugs was evaluated as the percentage of patients who responded to treatment. Discounting was not conducted because the time horizon of the analysis did not exceed 1 year. RESULTS: As a result of calculations the cost of the 1st year therapy with piribedil CR, pramipexole ER, ropinirole ER and rasagiline was 28,822, 20,810, 57,449 and 54,332 rubles respectively. The cost of the 1st year of therapy taking into account the change of therapy due to ineffectiveness is: 32,799, 26,300, 53,218 and 51,266 rubles per patient per year for piribedil CR, pramipexole ER, ropinirole ER and rasagiline respectively. CONCLUSIONS: BIA showed that the largest budget savings was achieved in the treatment of PD with pramipexole ER. Pramipexole ER in monotherapy resulted in cost savings worth 6,499 rub. (20%) vs. piribedil CR, 26,918 rub. (51%) vs. ropinirole ER and 24,966 rub. (49%) vs. rasagiline per patient per a year of therapy.